In the News

BIOCENTURY

August 21, 2018

Follow
Harbour BioMed
on WeChat

Back to list

BIOCENTURY

August 21, 2018

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmceutical Co. Ltd. (SZSE:002422).

Media Contact:

Harbour BioMed Public Relations

E-mail: pr@harbourbiomed.com